Results 161 to 170 of about 38,738 (212)
Some of the next articles are maybe not open access.
Diabetes Research and Clinical Practice, 2011
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications.
Michel, Marre, Alfred, Penfornis
openaire +2 more sources
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications.
Michel, Marre, Alfred, Penfornis
openaire +2 more sources
Emerging GLP-1 receptor agonists
Expert Opinion on Emerging Drugs, 2011Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become available for the treatment of type 2 diabetes. These agents exploit the physiological effects of GLP-1, which is able to address several of the pathophysiological features of type 2 diabetes.
Lund, Asger +2 more
openaire +3 more sources
GLP-1 receptor agonists in NAFLD
Diabetes & Metabolism, 2017Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (
Petit, Jean-Michel, Vergès, Bruno
openaire +2 more sources
The Diabetes Educator, 2015
Purpose Type 2 diabetes (T2D) imparts an increased risk of adverse health outcomes in patients unable to achieve glycemic control. Patient education and individualization of treatment are important for effective management of T2D. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of injectable glucose-lowering agents that lower A1C with ...
Curtis, Triplitt +1 more
openaire +2 more sources
Purpose Type 2 diabetes (T2D) imparts an increased risk of adverse health outcomes in patients unable to achieve glycemic control. Patient education and individualization of treatment are important for effective management of T2D. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of injectable glucose-lowering agents that lower A1C with ...
Curtis, Triplitt +1 more
openaire +2 more sources
Vitreous hemorrhage during GLP-1 receptor agonist treatment
Journal of the American Pharmacists Association, 2023The purpose of this case report is to describe a case of vitreous hemorrhage in a patient with a history of diabetic retinopathy and receiving dulaglutide for the management of type 2 diabetes mellitus (T2DM).A 64-year-old African American male with a past medical history of T2DM and severe diabetic retinopathy for 4 years was restarted on dulaglutide ...
Da Som, Kim +2 more
openaire +2 more sources
GLP-1 Receptor Agonists in Diabetic Kidney Disease
Clinical Journal of the American Society of Nephrology, 2021Ms. AM is a 42-year-old American Indian woman who is referred to nephrology clinic for progressive CKD. She developed type 2 diabetes at age 19. The patient also has hypertension, hyperlipidemia, and obesity.
Erin D. Michos, Katherine R. Tuttle
openaire +2 more sources
RCSB Protein Data Bank
ABSTRACT Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting millions of individuals worldwide. The burden of disease is significant, as demonstrated by high morbidity and mortality and billions of healthcare dollars spent. The pathophysiology of T2DM is complex, with eight primary deficits.
openaire +3 more sources
ABSTRACT Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting millions of individuals worldwide. The burden of disease is significant, as demonstrated by high morbidity and mortality and billions of healthcare dollars spent. The pathophysiology of T2DM is complex, with eight primary deficits.
openaire +3 more sources
Novel GLP-1 receptor agonists for diabetes
Expert Opinion on Investigational Drugs, 2011GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was approved in the mid-2000s, other agents with longer durations of action (that do not require twice-daily dosing) are now being developed.
openaire +2 more sources
Albiglutide: a unique GLP-1 receptor agonist
Expert Opinion on Biological Therapy, 2016Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval ...
openaire +2 more sources
Glp-1 Receptor Agonists Significantly Impair Taste Function
Physiology & BehaviorOver 10 % of the US population are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to combat obesity. Although they decrease cravings for foods, their influence on chemosensory function is unknown. We employed state-of-the-art quantitative taste and smell tests to address this issue.
Rafa, Khan, Richard L, Doty
openaire +2 more sources